Repligen Corporation to Present at J.P. Morgan 2026 Healthcare Conference
WALTHAM, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership,...
Day: December 18, 2025
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to...
“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine
Nature Medicine asked leading researchers to name their top clinical trial for 2026, from long-awaited vaccines for infectious diseases to...
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term...
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term...
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term...
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
Not for distribution to U.S. news wire services or dissemination in the United StatesWINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE)...
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer’s disease Clear and near-term...
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical...
Kane Biotech Announces Closing of Private Placement Offering with an Insider of the Company
Not for distribution to U.S. news wire services or dissemination in the United StatesWINNIPEG, Manitoba, Dec. 18, 2025 (GLOBE NEWSWIRE)...
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no additional warrants or adjustment provisionsCompany...
CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical...
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
Remaining $5.4 million debt was repaid through strategic equity conversion in common stock with no additional warrants or adjustment provisionsCompany...
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for...
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million
Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for...
Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union
PRESS RELEASE Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union Orphan designation confers market exclusivity, regulatory and...
Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union
PRESS RELEASE Memo Therapeutics AG’s Potravitug Granted Orphan Designation in the European Union Orphan designation confers market exclusivity, regulatory and...
CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries
Collaboration to leverage CAMP4’s RAP Platform® to accelerate development of novel antisense oligonucleotides (ASOs) for neurodegenerative and renal diseases CAMP4...